Potency of vascular risk factors as the basis for antihypertensive therapy
- PMID: 1486903
- DOI: 10.1093/eurheartj/13.suppl_g.34
Potency of vascular risk factors as the basis for antihypertensive therapy
Abstract
Hypertension is a powerful predisposing risk factor for cardiovascular disease at all ages and in both sexes. Epidemiological assessment indicates the largest risk ratios for stroke and congestive heart failure (CHF), but coronary heart disease (CHD) is the most common and most lethal sequela of hypertension. Examination of the risk of cardiovascular sequelae in the hypertensive population indicates that this is not uniform and varies over a 10-fold range, depending on the associated risk factors. Systolic pressure merits greater consideration than the diastole pressure because isolated systolic hypertension is a powerful cardiovascular risk at all ages. Furthermore, recent trials have indicated the benefit of therapy for systolic-based hypertension in the elderly, even using a diuretic, for coronary disease as well as stroke. Persons with hypertension have a high prevalence of associated cardiovascular risk factors, including elevated cholesterol, reduced HDL-C, diabetes, left ventricular hypertrophy (LVH), and obesity. About 9% under the age of 65 years have an associated overt cardiovascular disease; above age 65 about 30% are so afflicted. Each of these risk factors can double the risk associated with hypertension. Because they are so common, a large fraction of the disease sequelae of hypertension is attributable to these associated risk factors. The high risk of coronary disease in hypertensive patients is concentrated in those with a high total/HDL-cholesterol ratio, impaired glucose tolerance, high fibrinogen, ECG abnormalities, and cigarette smokers. Stroke risk in hypertensive persons is concentrated in those with cardiovascular disease, diabetes, atrial fibrillation, LVH and cigarette smoking.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Hypertension as a risk factor for cardiac events--epidemiologic results of long-term studies.J Cardiovasc Pharmacol. 1993;21 Suppl 2:S27-37. doi: 10.1097/00005344-199321002-00006. J Cardiovasc Pharmacol. 1993. PMID: 7692148 Review.
-
Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience).Am J Cardiol. 1996 Feb 22;77(6):6B-11B. doi: 10.1016/s0002-9149(97)89232-6. Am J Cardiol. 1996. PMID: 8848993 Review.
-
Goals of antihypertensive therapy.Drugs. 1995 Feb;49(2):161-75. doi: 10.2165/00003495-199549020-00002. Drugs. 1995. PMID: 7729325 Review.
-
[Hypertension as a function of age].Ital Heart J. 2000 Jun;1 Suppl 2:23-31. Ital Heart J. 2000. PMID: 10905125 Review. Italian.
-
Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure.Cardiovasc Drugs Ther. 1997 May;11 Suppl 1:199-212. doi: 10.1023/a:1007792820944. Cardiovasc Drugs Ther. 1997. PMID: 9211012 Review.
Cited by
-
Electrocardiographic left ventricular hypertrophy and mortality in an oldest-old hypertensive Chinese population.Clin Interv Aging. 2019 Sep 17;14:1657-1662. doi: 10.2147/CIA.S218106. eCollection 2019. Clin Interv Aging. 2019. PMID: 31571845 Free PMC article.
-
Drug selection for optimal treatment of hypertension in the elderly.Drugs Aging. 1997 Jul;11(1):19-26. doi: 10.2165/00002512-199711010-00003. Drugs Aging. 1997. PMID: 9237038 Review.
-
Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an asian multinational population.Clin Drug Investig. 1998;16(3):177-85. doi: 10.2165/00044011-199816030-00001. Clin Drug Investig. 1998. PMID: 18370538
-
Glucose homeostasis abnormalities among Cameroon patients with newly diagnosed hypertension.J Clin Hypertens (Greenwich). 2017 May;19(5):519-523. doi: 10.1111/jch.12959. Epub 2017 Jan 2. J Clin Hypertens (Greenwich). 2017. PMID: 28042916 Free PMC article.
-
Trends and risk factors for non-communicable diseases mortality in Nairobi slums (2008-2017).Glob Epidemiol. 2021 Nov;3:100049. doi: 10.1016/j.gloepi.2021.100049. Glob Epidemiol. 2021. PMID: 34977550 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical